Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk

G P Sava; H E Speedy; M C Di Bernardo; M J S Dyer; A Holroyd; N J Sunter; H Marr; L Mansouri; S Deaglio; L Karabon; I Frydecka; K Jamroziak; D Woszczyk; G Juliusson; K E Smedby; S Jayne; A Majid; Y Wang; C Dearden; A G Hall; T Mainou-Fowler; G H Jackson; G Summerfield; R J Harris; A R Pettitt; D J Allsup; J R Bailey; G Pratt; C Pepper; C Fegan; R Rosenquist; D Catovsky; J M Allan; R S Houlston

doi:10.1038/leu.2014.311

Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk

Leukemia. 2015 Mar;29(3):748-51. doi: 10.1038/leu.2014.311. Epub 2014 Nov 3.

Authors

G P Sava¹, H E Speedy¹, M C Di Bernardo¹, M J S Dyer², A Holroyd¹, N J Sunter³, H Marr³, L Mansouri⁴, S Deaglio⁵, L Karabon⁶, I Frydecka⁷, K Jamroziak⁸, D Woszczyk⁹, G Juliusson¹⁰, K E Smedby¹¹, S Jayne², A Majid¹², Y Wang¹, C Dearden¹³, A G Hall³, T Mainou-Fowler¹⁴, G H Jackson¹⁵, G Summerfield¹⁶, R J Harris¹⁷, A R Pettitt¹⁷, D J Allsup¹⁸, J R Bailey¹⁹, G Pratt²⁰, C Pepper²¹, C Fegan²², R Rosenquist⁴, D Catovsky¹³, J M Allan³, R S Houlston¹

Affiliations

¹ Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK.
² The Ernest and Helen Scott Haematological Research Institute, Department of Biochemistry and Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK.
³ Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
⁴ Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
⁵ Department of Medical Sciences and Human Genetics Foundation, University of Turin, Turin, Italy.
⁶ 1] Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland [2] Department and Clinic of Urology, Wroclaw Medical University, Wroclaw, Poland.
⁷ Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
⁸ Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
⁹ Department of Haematology, State Hospital, Opole, Poland.
¹⁰ Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Hematology and Transplantation, Lund University, Lund, Sweden.
¹¹ Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
¹² Medical Research Council Toxicology Unit, Leicester University, Leicester, UK.
¹³ Haemato-Oncology, Division of Pathology, The Institute of Cancer Research, Sutton, UK.
¹⁴ Haematological Sciences, Medical School, Newcastle University, Newcastle upon Tyne, UK.
¹⁵ Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
¹⁶ Department of Haematology, Queen Elizabeth Hospital, Gateshead, Newcastle upon Tyne, UK.
¹⁷ Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
¹⁸ Department of Haematology, Hull Royal Infirmary, Hull, UK.
¹⁹ Hull York Medical School and University of Hull, Hull, UK.
²⁰ Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.
²¹ Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
²² Cardiff and Vale National Health Service Trust, Heath Park, Cardiff, UK.

No abstract available

Publication types

Letter
Meta-Analysis
Research Support, Non-U.S. Gov't

MeSH terms

2',5'-Oligoadenylate Synthetase / genetics*
Alleles
Case-Control Studies
Chromosome Mapping
Chromosomes, Human, Pair 12 / chemistry*
Gene Frequency
Genetic Loci
Genetic Predisposition to Disease
Genome-Wide Association Study
Humans
Introns*
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Odds Ratio
Polymorphism, Single Nucleotide*
Risk

Substances

2',5'-Oligoadenylate Synthetase
OAS3 protein, human

Publication types

MeSH terms

Substances

Grants and funding